← Back to All US Stocks

AXGN Stock Analysis - Axogen, Inc. AI Rating

AXGN Nasdaq Electromedical & Electrotherapeutic Apparatus MN CIK: 0000805928
Recently Updated • Analysis: Mar 20, 2026 • SEC Data: 2025-12-31
AI Rating
SELL
78% Confidence

📊 AXGN Key Takeaways

Revenue: $225.2M
Net Margin: -7.0%
Free Cash Flow: $-2.9M
Current Ratio: 5.11x
Debt/Equity: 0.38x
EPS: $-0.34
AI Rating: SELL with 78% confidence

Investment Thesis

Despite strong revenue growth of 20.2% YoY and an impressive 74.3% gross margin, Axogen is unprofitable with negative operating income of -$7.8M and deteriorating net income that declined 57.6% YoY. The company is burning cash with negative free cash flow of -$2.9M while carrying substantial debt of $48.4M, creating significant financial strain that undermines growth quality.

AXGN Strengths

  • + Strong revenue growth of 20.2% YoY demonstrates market demand
  • + Excellent gross margin of 74.3% indicates pricing power and operational efficiency in core business
  • + Solid liquidity position with current ratio of 5.11x and $35.5M cash buffer

AXGN Risks

  • ! Persistent operating losses of -$7.8M indicate inability to convert revenue growth into profitability
  • ! Negative free cash flow of -$2.9M and operating cash flow of only $812K despite $225.2M revenue signals operational inefficiency
  • ! High debt burden of $48.4M with negative interest coverage ratio of -3.4x creates refinancing and solvency risk
  • ! Deteriorating net income (-57.6% YoY) and negative ROE/ROA suggest fundamental business model challenges

Key Metrics to Watch

AXGN Financial Metrics

Revenue
$225.2M
Net Income
$-15.7M
EPS (Diluted)
$-0.34
Free Cash Flow
$-2.9M
Total Assets
$221.7M
Cash Position
$35.5M

💡 AI Analyst Insight

Strong liquidity with a 5.11x current ratio provides a solid financial cushion.

AXGN Profitability Ratios

Gross Margin 74.3%
Operating Margin -3.5%
Net Margin -7.0%
ROE -12.2%
ROA -7.1%
FCF Margin -1.3%

AXGN vs Healthcare Sector

How Axogen, Inc. compares to Healthcare sector averages

Net Margin
AXGN -7.0%
vs
Sector Avg 12.0%
AXGN Sector
ROE
AXGN -12.2%
vs
Sector Avg 15.0%
AXGN Sector
Current Ratio
AXGN 5.1x
vs
Sector Avg 2.0x
AXGN Sector
Debt/Equity
AXGN 0.4x
vs
Sector Avg 0.6x
AXGN Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

AXGN Balance Sheet & Liquidity

Current Ratio
5.11x
Quick Ratio
3.31x
Debt/Equity
0.38x
Debt/Assets
41.9%
Interest Coverage
-3.37x
Long-term Debt
$48.4M

AXGN 5-Year Financial Trend

AXGN 5-year financial data: Year 2021: Revenue $127.4M, Net Income -$29.1M, EPS $-0.74. Year 2022: Revenue $138.6M, Net Income -$23.8M, EPS $-0.60. Year 2023: Revenue $159.0M, Net Income -$27.0M, EPS $-0.65. Year 2024: Revenue $187.3M, Net Income -$28.9M, EPS $-0.69. Year 2025: Revenue $225.2M, Net Income -$21.7M, EPS $-0.51.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Axogen, Inc.'s revenue has grown significantly by 77% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.51 indicates the company is currently unprofitable.

AXGN Growth Metrics (YoY)

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
-1.3%
Free cash flow / Revenue

AXGN Quarterly Performance

Quarterly financial performance data for Axogen, Inc. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2025 $48.6M $708.0K $0.01
Q2 2025 $47.9M $579.0K $0.01
Q1 2025 $41.4M -$3.8M $-0.08
Q3 2024 $41.3M -$1.9M $-0.04
Q2 2024 $38.2M -$1.9M $-0.04
Q1 2024 $36.7M -$6.6M $-0.15
Q3 2023 $37.0M -$4.1M $-0.10
Q2 2023 $34.5M -$6.7M $-0.16

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

AXGN Capital Allocation

Operating Cash Flow
$812.0K
Cash generated from operations
Stock Buybacks
$639.0K
Shares repurchased (TTM)
Capital Expenditures
$3.7M
Investment in assets
Dividends
None
No dividend program

AXGN SEC Filings

Access official SEC EDGAR filings for Axogen, Inc. (CIK: 0000805928)

📋 Recent SEC Filings

Date Form Document Action
Mar 18, 2026 4 xslF345X06/wk-form4_1773864674.xml View →
Mar 18, 2026 4 xslF345X06/wk-form4_1773864598.xml View →
Mar 2, 2026 4 xslF345X05/wk-form4_1772493414.xml View →
Mar 2, 2026 4 xslF345X05/wk-form4_1772493371.xml View →
Mar 2, 2026 4 xslF345X05/wk-form4_1772493346.xml View →

Frequently Asked Questions about AXGN

What is the AI rating for AXGN?

Axogen, Inc. (AXGN) has an AI rating of SELL with 78% confidence, based on fundamental analysis of SEC EDGAR filings.

What are AXGN's key strengths?

Strong revenue growth of 20.2% YoY demonstrates market demand. Excellent gross margin of 74.3% indicates pricing power and operational efficiency in core business.

What are the risks of investing in AXGN?

Persistent operating losses of -$7.8M indicate inability to convert revenue growth into profitability. Negative free cash flow of -$2.9M and operating cash flow of only $812K despite $225.2M revenue signals operational inefficiency.

What is AXGN's revenue and growth?

Axogen, Inc. reported revenue of $225.2M.

Does AXGN pay dividends?

Axogen, Inc. does not currently pay dividends.

Where can I find AXGN SEC filings?

Official SEC filings for Axogen, Inc. (CIK: 0000805928) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is AXGN's EPS?

Axogen, Inc. has a diluted EPS of $-0.34.

How is the AI analysis conducted?

Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.

Disclaimer: This analysis is generated by Claude AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 20, 2026 | Data as of: 2025-12-31 | Powered by Claude AI